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Background/aim: Chronic obstructive pulmonary disease (COPD) is a common disease characterized by persistent airflow limitation and
respiratory symptoms. It is a leading cause of morbidity and mortality all over the world. Our data on COPD in Turkey are limited. This
study was intended to examine the epidemiologic characteristics of COPD in the Turkish population, between 2012 and 2016.
Materials and methods: This population-based, descriptive, surveillance study examined physician-diagnosed COPD prevalence, incidence,
and mortality in Turkey. The database of the Social Security System of Turkey was scanned and ICD-10 J44.0-J44.9 codes for diagnostic and/
or therapeutic purposes were evaluated retrospectively.
Results: In 2016, there were 3,434,262 cases of COPD (56.2% men) in Turkey, and the mean age of patients was 61.62 ± 14.76 years. From
2012 to 2016, the annual overall prevalence rates of physician-diagnosed COPD rose from 4.3% to 5.8%, which was a 35.0% relative increase
(P < 0.05). In women, this rate rose from 3.7% to 5.1% (38% increase), and in men, it rose from 4.9% to 6.7% (37% increase). During the
study period, the overall incidence decreased from 8.5 per 1000 adults in 2012 to 6.3 per 1000 adults in 2016, representing a decrease of
26.6% (P < 0.001). The annual incidence rates of physician-diagnosed COPD decreased 25.4% in women and 27.9% in men. The overall
mortality was 4.3% in 2012, and 4.2% in 2016. The mortality rate in women was 3.5% in 2012 and 3.7% in 2016, and 5% in 2012 and 4.7%
in 2016 in men. The mean prevalence by region was 5.26% (range 3.79%–7.65%). The Black Sea region had the highest COPD prevalence.
Conclusion: COPD is a very common and serious cause of morbidity and mortality in Turkey, as it is worldwide. Current data will contribute
to a better understanding of the epidemiologic dimension of COPD in our country.
Key words: Chronic obstructive pulmonary disease, epidemiology, population characteristics, prevalence, incidence, mortality, health
information systems

1. Introduction
Chronic obstructive pulmonary disease (COPD) is a
preventable and treatable major public health problem. It
is often associated with a history of cigarette smoking and
is the primary contributor to mortality caused by chronic
lower respiratory diseases, which is the third leading cause
of death worldwide [1]. Although it is an important and
increasing global cause of morbidity and mortality, there
is still insufficient knowledge about COPD, and it is not
adequately diagnosed. The prevalence and mortality of
COPD are expected to increase, particularly in developing
countries such as Turkey, and the natural history of COPD
in the community is largely unknown, including in Turkey.

Accurate epidemiologic information is important in
chronic diseases, including COPD, for several reasons:
documenting of the impact of COPD on quality of life
and costs, helping to inform public health planning, and
efficiently planning future healthcare [2].
Turkey is a developing Eurasian country; it does not
yet have a nation-wide medical registry system solely
devoted to collecting data about various chronic diseases
such as COPD. The present study aimed to evaluate the
epidemiologic characteristics of COPD (prevalence,
incidence, and mortality) within the entire Turkish
population over a period of 5 years using the registry of
the Social Security System, which covers 98.6% of the
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population, and in this way provide a useful and reliable
resource for epidemiologic data about the Turkish
population [3].
2. Materials and methods
The data of this retrospective study were sourced exclusively
from the Social Security System of Turkey in the scope of a
cooperation protocol with the Social Security Institution.
All data were extracted from the Oracle database using the
Tool for Oracle Application Developers (TOAD) 9.6.0.27
program.
The Social Security System of Turkey collects and
collates data regarding all hospital admissions and
discharge registries in Turkey on an individual basis.
Since 1996, the tenth revision of the World Health
Organization International Statistical Classification of
Diseases and Related Health Problems (ICD-10) has
been used to code hospital admissions and discharges in
Turkey [4]. Individuals aged over 18 years were identified
as having physician-diagnosed COPD if they had 1 COPD
hospitalization and/or 1 COPD ambulatory care claim
as indicated by the following codes in the registry of the
Social Security System: J44.0-J44.9. Data related with the
population of Turkey during the study were acquired from
the website of the Turkish Institute of Statistics [5].
Incident cases were defined as individuals who had no
COPD-related healthcare presentations in the previous
year. To calculate the annual incidence rates from 2012 to
2016, we divided the number of individuals who developed
COPD in a given year by the number of individuals at
risk for COPD (the total population minus the number
of people with prevalent COPD in the previous year).
Prevalent cases were defined as individuals who had COPD
diagnoses with ICD codes J44.0-J44.9 and remained in the
study population until they died. To calculate the annual
prevalence rates of COPD in the population from 2012 to
2016, we divided the number of patients with COPD who
were alive at the end of each year by the census population
estimate of that same year. COPD deaths were defined as
individuals who had COPD diagnoses and died of any
cause during the study period (all-cause mortality). We
calculated the annual mortality rate from 2012 to 2016
by dividing the annual number of deaths in people with
COPD by the number of individuals with COPD in each
year.
In Turkey, pulmonologists initiate COPD treatment
according to regulations. Other general or family
practitioners usually refer patients who they suspect of
having COPD to pulmonologists. There is no referral
system in Turkey [6,7]. We used the criterion of a fixed
postbronchodilator ratio of forced expiratory flow in 1 s
(FEV1)/forced vital capacity (FVC) of less than 0.7 as the

primary indicator of airflow obstruction, as proposed by
the Global Initiative for Chronic Obstructive Lung Disease
(GOLD) in Turkey [8].
In the current analysis, we report the overall prevalence,
incidence, and mortality data in all physician-diagnosed
individuals with COPD from 2012 to 2016, but the
prevalence data of cities and regions are limited up to 2016.
The methodology is presented as flow chart (Figure 1).
The present study was approved by the Ethics
Committee and Institutional Review Board of Dr.
Abdurrahman Yurtaslan Oncology Hospital (November
14, 2018; 2018-11/136).
SAS Enterprise Guide 5.1 (SAS Institute Inc. Cary,
NC, USA) was used for statistical analysis of the collated
data. Graphs were drawn using Graphpad Prism 6.01
(GraphPad Software Inc., La Jolla, CA, USA). Continuous
variables are expressed as numbers or percentages where
appropriate. The Mann–Whitney U-test and χ2 tests were
used for comparisons; 2-tailed P-values of <0.05 were
accepted as statistically significant.
3. Results
In 2012, 466,457 COPD patients with a mean age of 65.59
± 16.63 years were diagnosed as having COPD for the first
time. In 2016, 359,392 patients with a mean age of 60.25 ±
15.45 years were newly diagnosed as having COPD (Table
1). There were 3,434,262 cases of COPD (56.2% men) in
Turkey in 2016. The overall mean age of the patients was
61.62 ± 14.76 years. The mean age of men and women was
61.16 ± 14.24 years and 62.21± 15.38 years, respectively;
31.3% of the patients were aged over 70 years. From 2012
to 2016, the age of diagnosis decreased both in males
and females, and women were diagnosed at a later age
compared with men (Figure 2).
From 2012 to 2016, the overall annual prevalence rates
of physician-diagnosed COPD rose from 4.3% to 5.8%,
which was a 35.0% relative increase (P for trend < 0.05). In
the same period, the annual prevalence rates of physiciandiagnosed COPD in women rose from 3.7% to 5.1% (38%,
P for trend < 0.05). This rate rose from 4.9% to 6.7% (37%,
P for trend < 0.01) in men. The prevalence rate increase
was the same in both sexes. COPD rates were higher in
men than in women at any year interval, and there was
an increasing trend in COPD prevalence rates among both
sexes (Figure 3).
During the study period, the overall incidence rate of
physician-diagnosed COPD decreased from 8.5 per 1000
adults in 2012 to 6.3 per 1000 adults in 2016, representing
a relative decrease of 26.6% (P < 0.001). In the same
period, the annual incidence rates of physician-diagnosed
COPD in women decreased from 6.9 per 1000 adults to
5.1 per 1000 adults (25.4%, P for trend < 0.05). This rate
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Figure 1. Flow chart of methodology.

Table 1. Demographic characteristics of newly-diagnosed patients with COPD.
Years
2012
2013
2014
2015
2016

Sex

Newly-diagnosed
patients with COPD (n)

Mean age ± SD

F

189,704

65.59 ± 16.63

M

276,753

64.37 ± 15.00

F

172,331

63.80 ± 16.27

M

247,083

62.17 ± 14.65

F

162,916

63.36 ± 16.24

M

232,435

61.50 ± 14.70

F

161,858

61.66 ± 16.39

M

229,684

59.93 ± 14.77

F

149,317

61.35 ± 16.37

M

210,075

59.48 ± 14.71

Total
(n)

Mean age ± SD

466,457

64.87 ± 15.95

419,414

62.84 ± 15.35

395,351

62.26 ± 15.38

391,542

60.64 ± 15.49

359,392

60.25 ± 15.45

COPD: Chronic obstructive pulmonary disease; SD: Standard deviation; F: Female; M: Male
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Figure 2. Average age of newly-diagnosed patients with COPD in Turkey, from 2012
to 2016.

Figure 3. Annual overall and sex-stratified physician-diagnosed COPD prevalence
rates in Turkey, from 2012 to 2016.

decreased from 10.2 per 1000 adults to 7.4 per 1000 adults
(27.9%, P for trend < 0.001) in men. Incidence rates were
higher among men than in women at any year interval,
and incidence rates had a decreasing trend in both sexes
(Figure 4).
Mortality rates were significantly higher in men than
in women at any year interval. The mortality rate was 3.5%
in 2012 and 3.7% in 2016 in women (P > 0.05), and 5% in
2012 and 4.7% in 2016 in men (P > 0.05). There was no

significant difference between the overall mortality rate in
2012 and 2016 (4.3% vs. 4.2%) (Figure 5).
The mean prevalence by region was 5.26% (range,
3.79%–7.65%). The Black Sea region had the highest
COPD prevalence (Table 2). The prevalence of COPD
varied considerably by city: 9.4%–11.5% in Ardahan,
Kastamonu, and Çankırı, and 1.8%– 2.79% in Hakkari,
Şırnak, and Van. The median prevalence by city was 5.68%
(range, 1.8%–11.5%) (Figure 6).
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Figure 4. Annual overall and sex-stratified physician-diagnosed COPD incidence rates
in Turkey, from 2012 to 2016.

Figure 5. Annual overall and sex-stratified physician-diagnosed COPD mortality rates
in Turkey, from 2012 to 2016.

4. Discussion
This population-based study reported overall prevalence,
incidence, and mortality data in all individuals with
physician-diagnosed COPD over a 5-year period in
Turkey. We found that the prevalence of COPD increased
by 35.0%, the incidence of COPD decreased by 26.6%, and
the overall all-cause mortality of individuals with COPD
was 4.2% between 2012 and 2016 in Turkey. Most of the
increase in prevalence was borne by men. We also found
the incidence of COPD to be decreasing (more pronounced
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in men than in women) and all-cause mortality stability,
suggesting that COPD management strategies were having
a beneficial effect.
Prevalence is dependent on incidence and duration
of a disease. The prevalence of COPD can be evaluated
through different approaches: physician-diagnosed COPD
prevalence, the prevalence of respiratory symptoms
revealed in questionnaires, and the prevalence of
spirometry and airflow limitation. Also, it is difficult to
compare published studies because of the great variability
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Table 2. The prevalence rates by region in Turkey in 2016.
Region

Prevalence (%)

Black Sea

7.65

Central Anatolia

6.13

Aegean

5.68

Eastern Anatolia

4.84

Marmara

4.48

Mediterranean

4.23

Southeast Anatolia

3.79

that exists in terms of the designs, diagnostic criteria, and
age ranges used. Rycroft et al. highlighted this situation
in their review, showing that the prevalence ranged from
0.2% to 37% between different countries [9]. For example,
in China, Zhong et al. interviewed participants using a
standardized questionnaire and performed spirometry
on all eligible participants to determine the COPD
prevalence among citizens aged 40 years or older, and
found the overall prevalence of COPD was 8.2% (men,
12.4%; women, 5.1%) [10]. In India, an average prevalence
of 3.5% was reported in a study with a large population

(INSEARCH) undertaken at 16 different centers in
the country [11]. In the PLATINO study, individuals
were invited to answer a questionnaire and underwent
anthropometry and spirometry. The prevalence of COPD
ranged from 7.8% to 20% in 5 major Latin American
cities [12]. In the BOLD study, the prevalence of stage II
or higher COPD was 10.1% overall, 11.8% for men, and
8.5% for women [13]. However, in the results of screening
studies, the prevalence of physician-diagnosed COPD was
different. In Austria, Schirnhofer et al. surveyed a sexstratified, population-based sample of 2200 adults ≥40
years of age, and they found that the overall prevalence
of mild COPD was 26.1%, whereas the prevalence of
moderate or severe COPD was 10.7%. Furthermore, a
doctor diagnosis of COPD was reported by only 5.6% of
participants [14]. In the United Kingdom, from 1990 to
1997 the annual prevalence rates of physician-diagnosed
COPD in women rose from 0.80% to 1.36%, and 1.3% to
1.6% in men. The prevalence rate increased by 68.7% in
women compared with 25.3% in men, and COPD rates
were higher in men than in women at any age interval [15].
Our prevalence estimates of COPD are consistent with
these studies. We found that the overall prevalence rates
of physician-diagnosed COPD rose from 4.3% to 5.8%, in
women it rose from 3.7% to 5.1%, and in men it increased

Figure 6. Prevalence of physician-diagnosed COPD by city in Turkey, in 2016.
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from 4.9% to 6.7%. COPD rates were higher in men than
in women at any year interval.
To the best of our knowledge, although a number
of regional reports are available, there have been no
previous large-scale, population-based studies of trends
in COPD prevalence, incidence, and mortality in Turkey.
COPD prevalence, risk factors, and burden of disease
were evaluated in the BOLD study in Adana by Kocabaş
et al. between December 2003 and January 2004. The
preliminary results of this study showed that COPD
prevalence was about 19.1% in subjects aged over 40 years
in Adana [16]. Günen et al. evaluated the prevalence of
COPD in a population randomly selected from urban
and rural regions of Malatya. Through a respiratory
questionnaire and postbronchodilator spirometry
performed in 1160 participants aged over 18 years, COPD
prevalence was found as 6.9%. The prevalence of COPD
was 18.1% in current smokers, and 4.5% among young
smokers [6]. Deveci et al. evaluated 1206 participants
aged >18 years using a respiratory questionnaire and
spirometry in order to determine the prevalence of COPD
in Elazığ. The prevalence of COPD in those aged ≥18 years
was 4.5% (female 2.5%; male 6%), and the prevalence in
participants aged ≥45 years was 11.5% (female 5.9%; male
15.1%) [17]. Çetinkaya et al. performed a crosssectional
survey with 1023 subjects aged 20–83 years, and they
found the prevalence was higher in males (17.8%) than in
females (10.0%) [18]. Our prevalence estimates of COPD
are lower than those found in these screening studies.
These differences can be explained by the fact that the
COPD prevalence in our study was based on symptomatic
patients who presented to a physician and not on broadbased spirometric findings or questionnaires.
The incidence of COPD varies greatly between
countries, but it is difficult to compare estimates because
they are reported in different units and over different
lengths of time. De Marco et al. found the incidence rate of
COPD as 2.8 cases/1000/year in Italy [19]. In Sweden, the
10-year cumulative incidence of COPD was estimated at
8.2% with the British Thoracic Society criteria, and 13.5%
with the GOLD criteria [20]. Although the incidence
COPD has shown an increasing trend over the years, there
has been an overall decrease in the last 10 years. Gershon
et al. reported that the incidence of COPD decreased
in Ontario from 11.8 per 1000 adults in 1996 to 8.5 per
1000 adults in 2007, representing a relative decrease of
28.3% [21]. Also in our study, the overall incidence rate of
physician-diagnosed COPD decreased from 8.5 per 1000
adults in 2012 to 6.3 per 1000 adults in 2016, representing
a 26.6% decrease. The incidence of COPD also varied
between the sexes. In the same study by Gershon et al.,
the incidence of COPD was demonstrated to be decreasing
in men more notably than in women. The incidence rates
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had a decreasing trend in both sexes [21]. In Australia,
the incidence of COPD decreased in men between 1998
and 2003, but increased in women [22]. We found the
annual incidence rates of physician-diagnosed COPD in
women decreased from 6.9 per 1000 adults to 5.1 per 1000
adults (25.4%) between 2012 and 2016, and from 10.2 per
1000 adults to 7.4 per 1000 adults (27.9%) in men. Our
incidence rates also had a decreasing trend in both sexes.
All these studies and ours suggest improvements in COPD
management.
The real extent and impact of COPD on mortality in
the general population is incompletely known. Similar to
prevalence and incidence studies, the reported mortality
rates among patients with COPD and length of followup differ, which results in difficulties when comparing
studies. In Sweden, the OLIN COPD study longitudinally
compared patients with and without COPD, and the
mortality rate was significantly higher among subjects
with COPD (5.1% vs. 3.0%) [23]. In the study by Camp
et al., men had a higher prevalence (4.7% vs. 4.0%) and a
higher all-cause mortality rate (5.4% vs. 4.1%) than women
in 2003/2004. The authors also found a trend of decreasing
age-standardized mortality rates from 1992/1993 to
2000/2001, followed by a stable mortality rate from 2001
onward for both men and women with COPD in Canada
[24]. Similar to these results, Gershan et al. found that the
all-cause mortality rate decreased from 5.7% in 1996 to
4.3% in 2007, representing a 24.0% relative decrease. This
decrease was greater in men than in women. Mortality
rates were significantly higher in men at any year interval
[21]. We found mortality rates of 3.5% in 2012 and 3.7% in
2016 in women, and 5% in 2012 and 4.7% in 2016 in men,
and the overall mortality rates in 2012 and 2016 were 4.3%
and 4.2%, respectively. The mortality rate in women with
COPD increased minimally but then plateaued, as in men.
Decreasing COPD mortality rates are also consistent with
improvements in COPD management.
When Turkey is examined in terms of regional
distribution of prevalence, it can be seen that the prevalence
is heterogeneous. The mean prevalence by region was
5.26%, and by city it was 5.68%. The Black Sea region had
the highest COPD prevalence. This may be related to the
presence of an elderly population in the Black Sea region
[25]. In the case of smoking in our country, men between
the ages of 35 and 44 years constitute the age group that
smokes the most tobacco products, at 50.6% [5]. According
to these data, the prevalence of COPD in Turkey would
be expected to be higher than we found. The case data
were exclusively sourced from the Social Security System.
We used physician-diagnosed COPD and, therefore,
underestimated the prevalence. Additional research is
needed to determine the underlying causes of geographic
distributions, which might be related to geographic
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variations in other factors, including diagnostic practices,
access to effective health interventions, cigarette smoking,
and occupational and environmental exposures.
This study has a series of advantages, the principal of
which is that it covered the entire population of Turkey
because the Social Security System covers 98.6% of the
population. Accordingly, there should be no selection bias
present. Furthermore, this is the first large, populationbased study to examine trends in COPD prevalence,
incidence, all-cause mortality, and regional trends. A
number of limitations of this analysis must be mentioned.
The main limitation is that we used physician-diagnosed
COPD, which is only the tip of the iceberg and may
underestimate the true prevalence. Secondly, in daily
practice, the actual cause of death remains in the background
or multiple diagnoses can be made, so the mortality rate is
the rate of all-cause mortality. Thirdly, this is a descriptive
study and does not address factors such as environmental,
occupational, socioeconomic, and healthcare-related
factors in determining COPD morbidity, mortality, and
health service use. By providing a variety of data such
as demographic data in the registration information in
the Social Security System database, information about
the factors affecting environmental and occupational
exposures in COPD development can be obtained.

In conclusion, differences in the results between
countries may be due to differences in notification
systems, as well as differences in smoking behaviors in
countries, environmental factors, infections, and the
distribution of genetic factors. Our results suggest that
COPD management strategies are having a benefit in
Turkey. According to these results, COPD is a much
larger health problem in Turkey, but the actual extent of
COPD will only emerge when nondiagnosed candidates
who self‑report good health are included in investigations.
We hope that these results will stimulate healthcare
providers and increase the attention of policy-makers to
take action towards this important disease. We hope our
results will have positive effects on COPD prevention and
management strategies. Finally, we think that the findings
of our study will provide a basis for further investigations.
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